ABSTRACT
Objectives: Recognition of fatal coagulopathies in patients with carcinoma of prostate by carrying out platelet count, PT and APTT
Study Design: A case-control study
PLACE AND DURATION: Samples collected from patients attending ISRA University Hospital, Hyderabad, Liaquat University of Medical and Health Sciences Hospital Hyderabad and NIMRA Jamshoro from June 2011 to November 2011. Study was conducted in the Pathology department, ISRA University Hospital, Hyderabad. Duration of study was six months
Methodology: Cases were patients with prostatic carcinoma who were diagnosed on biopsy examination. Controls were normal healthy randomly selected age matched adult males from Hyderabad without prostatic carcinoma. A total of one hundred subjects were included in the study. They were divided in two groups as follows; Group-I: Patients-Diagnosed cases of carcinoma of prostate. Group - II: Control - Normal subjects of the same age group
Results: A total number of 50 cases with the history of prostatic carcinoma were included according to the criteria mentioned in the material and method section. The frequencies of different variables were taken for platelet count, prothrombin time and activated partial thromboplastin time. In Group -1 [Cases], the mean platelet count was 197.52 x 10[3] in patients with advance age and in Group - II [Controls], the mean platelet count was 286.06 x 10[3]. The mean platelet count of cases and control is shown in Table -1.In the Group -1 [Cases] the mean PT value was 16.95 seconds and in Group - II [Controls] the mean PT value was 11.92 seconds. The mean PT of cases and control is shown in Table - II. In the Group -1 [Cases] the mean APTT value was 36.88 seconds and in Group - II [Controls] the mean APTT value was 30.94 seconds. The mean APTT of cases and control is shown in Table-III
Conclusion: Early analysis and recognition of coagulopathies in patients with carcinoma of prostate by carrying out platelet count, PT and APTT should be sorted out to help the patients in terms of treatment or diagnosis or prevention of fatal complications. Disseminated intravascular coagulation is the most frequently reported disorder but, in spite of its long-time recognition, its treatment remains controversial. Our results suggest that platelet count; PT and APTT are altered in patients with prostate cancer. Further study is needed to elucidate the underlying mechanism and clinical significances of such a phenomenon among patients with prostate cancer
ABSTRACT
Analysis and recognition of coagulopathies in patients with carcinoma of prostate by carrying out platelet count and D-dimers level. Case-control study. This study was conducted at ISRA Hospital, Hyderabad, Liaquat University of Medical and Health Sciences Hospital Hyderabad and NIMRA Jamshoro for a period of six months from from June 2011 to November 2011. Cases were patients with prostatic carcinoma who were diagnosed on biopsy examination. Controls were normal healthy randomly selected age matched adult males from Hyderabad without prostatic carcinoma. A total of one hundred subjects were included in the study. In Group I [Cases], the mean platelet count was 197.52 x 103 and in Group II [Controls], the mean platelet count was 286.06 x 103. In Group I [Cases], the mean D-dimers level was 0.692 mg/L and in Group II [Controls], the mean D-dimers level was 0.146 mg/L. Coagulopathies are frequently associated with prostate cancer and should be known to urologists and oncologists because they may compromise short-term prognosis and influence therapeutic strategies. Our results suggest that platelet count and D-dimer levels are altered in patients with prostate cancer